News
Comment: How industry unity in femtech can be a catalyst for women’s health innovation
By Sheena D. Franklin, founder of K’ept Health, a women’s focused heath informatics company.
The femtech industry is at a turning point. What started as a niche sector has evolved into a multi-billion-dollar powerhouse addressing critical gaps in women’s health. Yet, despite this rapid growth, femtech founders still face major roadblocks—limited investment, regulatory hurdles, and the lack of comprehensive data needed to drive real change.
For femtech to truly transform women’s health and establish itself as an essential pillar of healthcare innovation, we need to move beyond working in isolation. A more connected, collaborative ecosystem will help shift the perception of femtech from a specialized market to a driving force behind broader healthcare reform.
Breaking silos to build a stronger femtech ecosystem
One of the biggest challenges in femtech today is fragmentation. Companies are making incredible strides in fertility, menopause, chronic disease management, and more—but often in isolation. Without deeper collaboration, we risk redundancy—tackling the same problems separately instead of driving collective progress.
This isn’t just an obstacle—it’s a missed opportunity. Too many femtech founders navigate regulatory hurdles, consumer trust issues, and market education barriers alone, without tapping into the collective knowledge of their peers. The truth is, no single company can solve all the unmet needs in women’s health on its own. But by sharing insights, resources, and lessons learned, founders can accelerate progress—not just for their own companies, but for the entire industry.
Other sectors have successfully made this shift. Fintech, for example, has thrived by forming alliances to drive financial inclusion. Femtech can take a similar approach by fostering open dialogue, creating strategic partnerships, and embracing collaboration as a growth strategy. When femtech companies support one another, the industry moves faster, innovation happens more efficiently, and—most importantly—women get better solutions, sooner.
The power of data collaboration to overcome silos
Breaking down silos is one thing—but real progress happens when companies collaborate on data. Many femtech companies collect valuable user-generated health data, yet without a secure way to share and analyse these insights, the industry misses a huge opportunity to drive systemic change.
Understandably, concerns over competitive advantage and patient trust make data-sharing a tricky subject. But companies that find responsible, privacy-focused ways to collaborate on data will lead the next wave of women’s health innovation.
A prime example is the FemIndex by K’ept Health, which is pioneering responsible data collaboration in women’s health. Using federated machine learning, the FemIndex allows secure data sharing across multiple femtech sectors while protecting user privacy. Instead of working in silos, companies can contribute to and benefit from a diverse, high-quality dataset that strengthens AI models, accelerates drug discovery and improves precision medicine.
Industry-wide collaboration is also taking shape through initiatives like The Wonder Woman Collective, which unites femtech companies to streamline specialty care, close coverage gaps, and reduce costs for conditions like migraines, hypothyroidism, and PCOS. This collective is also working to engage payers, conduct cost-saving studies, and advocate for increased federal investment in women’s health. As part of the initiative, participating companies will share anonymized medical records to support R&D efforts.
By combining specialised care platforms with advanced data-sharing infrastructures, we can create a network-driven approach that strengthens femtech’s ability to scale while accelerating progress across the entire industry.
Strength in numbers: Industry standards, policy, and investment
Beyond technology and data, a united femtech sector can wield more influence in shaping policy, investment trends, and regulatory frameworks.
Setting industry standards is key to solidifying femtech as a major force in healthcare. By defining best practices for women’s health technologies, femtech leaders can ensure innovations are safe, effective, and widely trusted. Standardized guidelines also make it easier to secure regulatory approval, attract investors, and drive adoption.
A unified femtech industry can also push for better reimbursement models, clear clinical validation pathways, and stronger partnerships with healthcare providers. Working together, femtech leaders can advocate for insurance coverage that makes solutions more affordable and accessible. Deeper collaboration with hospitals and health systems will drive mainstream adoption and bridge the gaps in traditional care models—positioning femtech as an integral part of modern healthcare.
A united femtech future
Other industries have shown that competitors can work together to drive collective success. In the automotive sector, manufacturers collaborate on safety standards and emissions regulations, raising industry-wide standards while still competing in the market. In pharma, companies share research data to accelerate drug discovery, recognizing that advancing healthcare benefits everyone.
Femtech must do the same. The question is no longer whether should we work together—it’s how quickly we can embrace this shift. The future of femtech depends on our willingness to share knowledge, advocate collectively, and build a unified front that cements femtech as a critical part of the healthcare landscape.
Now is the time to move forward—together.
Sheena D. Franklin is founder of K’ept Health, a women’s focused heath informatics company. He other roles include chair of the Women’s Health Working Group for the Consumer Technology Association, where she leads standards creation for women’s health technology, and a trusted advisor to the American Medical Association and the Aspen Institute.
Hormone therapy started in peri- or early post-menopause was linked to a 22 per cent lower risk of cardiovascular events in women with vasomotor symptoms in a recent study.
The findings came from an observational analysis of 20 years of health data and do not show that hormone therapy caused the reduction in cardiovascular risk.
The association was strongest among Black women and women who started treatment within 10 years of menopause onset, although researchers cautioned that the findings should not guide clinical practice.
The study is the first of its kind in the US to assess the risk of future cardiovascular events among women with vasomotor symptoms who use hormone therapy during peri- and early postmenopause.
Samar R. El Khoudary, professor and chair of the Department of Epidemiology at the VCU School of Public Health and one of the study’s senior researchers, said: “The menopause transition represents a critical window for understanding how hormone therapy may relate to cardiovascular disease risk. Our findings suggest that timing of initiation may influence cardiovascular outcomes.”
The researchers stressed that the findings do not support using hormone therapy to prevent cardiovascular disease.
Potential benefits must also be weighed against risks, including the increased breast cancer risk observed with longer-term use.
The study was not a randomised controlled trial, the gold-standard method for testing biomedical treatments.
Rebecca C. Thurston, associate dean for Women’s Health Research at the University of Pittsburgh School of Medicine and one of the study’s senior researchers, said: “These findings point to women with vasomotor symptoms as those who may show cardiovascular benefit from hormone therapy initiated during the perimenopause and postmenopausal years.
“However, conclusions should be tempered by the observational nature of the study, and findings should not guide clinical practice.”
Vasomotor symptoms, meaning hot flushes and night sweats, affect up to 80 per cent of women during the menopause transition and last for an average of seven to ten years.
Their frequency and severity build through perimenopause and typically peak in early postmenopause.
Hormone therapy replaces oestrogen and progesterone that women’s bodies stop producing after menopause and is currently the most effective treatment for these symptoms.
Clinical trials led by the Women’s Health Initiative in the early 2000s raised concerns about hormone therapy’s impact on heart disease, stroke, breast cancer and other risks, leading to years of reluctance among patients and providers to use the treatment.
El Khoudary said: “Hot flashes and night sweats have a significant impact on a woman’s quality of life and ability to work productively.
“While hormone therapy is an effective treatment for these symptoms, questions have remained about its cardiovascular effects, particularly the importance of when treatment is initiated during the menopause transition.”
More recent research suggests the effects of hormone therapy on the heart and vascular system may vary by age and treatment timing, with women younger than 60 who start treatment closer to menopause onset having different levels of risk.
In 2026, the US Food and Drug Administration removed “black box” warnings from hormone therapy products, reflecting evolving evidence on the benefits and risks of treatment.
Researchers from Virginia Commonwealth University and the University of Pittsburgh analysed data from more than 2,700 women taking part in the Study of Women’s Health Across the Nation (SWAN).
The women reported vasomotor symptoms and had not previously experienced cardiovascular events.
Clinical data collected between 1997 and 2017 were used to examine whether women who started hormone therapy for vasomotor symptoms were more or less likely to experience stroke, congestive heart failure, heart attack or revascularisation procedures than women who did not start treatment.
El Khoudary said: “By using data from the SWAN study, we essentially were able to emulate a series of hypothetical clinical trials to gain a deeper understanding into how hormone therapy taken to mitigate vasomotor symptoms during peri- and early postmenopause influences cardiovascular risk over time.
“It allowed us to examine clinically meaningful cardiovascular disease events over long-term follow-up in a population and treatment window that has been challenging to study prospectively.”
Starting hormone therapy during peri- or early postmenopause was associated with an estimated 22 per cent lower risk of cardiovascular disease events.
Women who began hormone therapy within 10 years of menopause onset had an estimated 27 per cent lower risk compared with women who did not start treatment.
Among Black women, starting therapy during peri- or early postmenopause was associated with an estimated 49 per cent lower risk of cardiovascular disease events.
No clear reduction was seen among women who started therapy more than 10 years after menopause onset or among White women and other racial and ethnic groups.
El Khoudary said: “The differences in cardiovascular outcomes by race and ethnicity are notable, particularly because Black women are more likely to experience severe vasomotor symptoms.
“These findings highlight the need to better understand how hormone therapy timing may influence cardiovascular outcomes across diverse populations.”
It remains unclear why cardiovascular risk differed according to when hormone therapy was started, although researchers believe differences in blood vessel health with age may play a role.
Small bowel microbiome differences between women and men may help explain why some conditions are more common in women, a study suggests.
The small bowel microbiome is the community of microorganisms living in this part of the digestive tract, where they play vital roles in immune function, metabolism and hormonal regulation.
Researchers found differences between women and men in the composition and organisation of these microbial communities. One bacterial community containing Granulicatella was found only in women.
The study was conducted by investigators at Cedars-Sinai Health Sciences University.
Ruchi Mathur, director of clinical research and clinical operations for the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and corresponding author of the study, said: “One intriguing finding was a bacterial community containing Granulicatella, which we found only in women.
“Bacteria in this community appear at increased levels in women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome.”
The researchers also identified differences between women and men in how microbes in the small bowel produce fructans, complex carbohydrates known to trigger digestive symptoms in irritable bowel syndrome (IBS).
IBS is far more common in women than men.
Mathur, who is also a professor of medicine, said: “Our findings show that biological sex is a critical variable in the small bowel microbiome.
“We must consider it as we move toward more personalised approaches to understanding and treating disease.”
An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Hormonal health2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur1 week agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Mental health1 week agoUK study aims to transform maternity care for high-risk pregnancies
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests
Motherhood2 weeks agoThousands of UK women develop undiagnosed PTSD after childbirth each year – study